Skip to content
The Policy VaultThe Policy Vault

Jakafi (ruxolitinib tablets) — Cigna

Graft-Versus-Host Disease, Chronic

Initial criteria

  • Patient age ≥ 12 years
  • Patient has tried one conventional systemic treatment for graft-versus-host disease

Approval duration

1 year